Invasive pneumococcal disease in Catalonian elderly people, 2002-2009: Serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era

Vaccine

Volumn 29, Issue 43, 2011, Pages 7430-7434

  Vila Corcoles, Angel ^a   Ochoa Gondar, Olga ^a   Gomez Bertomeu, Frederic ^b   Raga Luria, Xavier ^c  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c Hospital Santa Tecla   (Spain)

Author keywords

Elderly; Incidence; Pneumococcal invasive disease; Pneumococcal vaccines; Serotype coverage

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTHRITIS; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; BODY FLUID; EMPYEMA; MENINGITIS; PERITONITIS; PLEURA EFFUSION; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; SEPSIS; SEROTYPE; SPAIN; STREPTOCOCCUS;

AGED; AGED, 80 AND OVER; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; POPULATION SURVEILLANCE; SEROTYPING; SPAIN; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 80053452159     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.066     Document Type: Article

References (20)

1. Ortqvist A., Hedlund J., Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005, 26:563-574.
2. Fedson D.S., Musher D.M. Pneumococcal polysaccharide vaccine. Vaccines 2003, 529-588. Saunders, Philadelphia. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
3. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19(3):187-195.
4. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18):1737-1746.
5. Centers for Disease Control Prevention Progress in introduction of pneumococcal, conjugate vaccine worldwide, 2000-2008. MMWR Morb Mortal Wkly Rep 2008, 57:1148-1151.
6. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294(16):2043-2051. Active Bacterial Core Surveillance Team.
7. Croxtall J.D., Keating G.M. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs 2009, 11(5):349-357.
8. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Prevention of pneumococcal disease among infants and children-use of 13valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR Recommendations 2010; Reports 59(RR11), 1-18.
9. Jackson L.A., Janoff E.N. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008, 47:1328-1338.
10. Web de l'estadística oficial de Catalunya. Idescat. Available at:. Accessed 20 September 2010. http://www.idescat.cat/.
11. Vila-Córcoles A., Ochoa-Gondar O., Ester F., Sarrá N., Ansa X., Saún N., et al. Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up. BMC Public Health 2006, 6:231.
12. Vila Córcoles A., de Diego Cabanes C., Salsench Serrano E., Saún Casas N Cover with conjugated heptavalent pneumococcal vaccine in the child population of Tarragona-Valls. Aten Primaria 2007, 39(9):507. Spain [in spanish].
13. Fenoll A., Granizo J.J., Aguilar L., Giménez M.J., Aragoneses-Fenoll L., Hanquet G., et al. Temporal trends of invasive Streptococcus pneumonia serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009, 47(4):1012-1020.
14. Imöhl M., Reinert R.R., van der Linden M. Adult invasive pneumococcal disease between 2003 and 2006 in North-Rhine Westphalia, Germany: serotype distribution before recommendation for general pneumococcal conjugate vaccination for children <2 years of age. Clin Microbiol Infect 2009, 15(11):1008-1012.
15. Park I.H., Pritchard D.G., Cartee R., Brandao A., Brandileone M.C., Nahm M.H. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007, 45:1225-1233.
16. Lepoutre A., Varin E., Georges S., Gutmann L., Lévy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 2005, 13:18962. Available at:,. Accessed 15 January, 2011. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18962.
17. Ardanuy C., Tubau F., Pallares R., Calatayud L., Domínguez M.A., Rolo D., et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction: 1997-2007. Clin Infect Dis 2009, 48(1):7-64.
18. Tsigrelis C., Tleyjeh I.M., Lahr B.D., Nyre L.M., Virk A., Baddour L.M. Trends in invasive pneumococcal disease among older adults in Olmsted County, Minnesota. J Infect 2009, 59(3):188-193.
19. Fry A.M., Zell E.R., Schuchat A., Butler J.C., Whitney C.G. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2002, 21:303-311.
20. Zangeneh T.T., Baracco G., Al-Tawfiq J.A. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections. Expert Rev Vaccines 2011, 10(3):345-353.